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CHARACTERIZATION OF NAÏVE IMMUNE CELL SUBSETS IMPORTANT IN 
HIV/SIV PATHOGENESIS AS A BASELINE FOR RNASEQ DECONVOLUTION  
JESSICA NGUYEN 
ABSTRACT 
 The human immunodeficiency virus-1 (HIV-1) currently infects 35 million people 
globally. HIV preferentially infects CD4+ T cells, a critical component of the host 
immune system, causing their rapid depletion, which has a broad negative impact on host 
immunity. Chronic HIV infection also results in increased expression of inhibitory 
immune regulatory proteins, which is associated with impaired functionality of a wide 
range of immune cells. This clinical phenomenon, referred to as “immune exhaustion,” 
precludes the slow and eventual failure of host immunity against co-infecting pathogens 
and is the hallmark of AIDS-related disease.  
In Aim 1 of our studies, we used whole blood from Indian-origin rhesus monkeys 
to distinguish 12 discrete immune cell subsets utilizing antibody staining and flow 
cytometric cell sorting. The segregated “naïve” (uninfected) cell subsets will be 
characterized by RNASeq gene expression analysis, and will be used as the baseline 
population for a bioinformatics “deconvolution” method comparing the same cell subsets 
from simian immunodeficiency virus (SIV)-infected cell populations. We successfully 
developed an antibody panel that distinguishes activated and resting CD4+ T cells, 
activated and resting CD8+ T cells, activated and resting B cells, activated and resting NK 
cells, plasmacytoid dendritic cells, myeloid dendritic cells, and monocytes. We also 
developed a separate isolation protocol for neutrophils using different densities of 
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Percoll. Finally, we optimized cell sorting of CD4+ and CD8+ T cells in order to obtain 
sufficient amounts of high quality RNA for future RNASeq gene expression analysis.  
As an adjunct to our above work, in Aim 2 of our experiments we sought to 
quantify the expression of immune inhibitory proteins that are increased upon the various 
cell subsets during SIV infection. We set out to optimize an antibody panel targeting 
three proteins of interest, PD-L1, LAG-3, and TIM-3, for the study of whole blood from 
SIV-infected rhesus monkeys. This data will be used to compliment our RNASeq dataset 
developed in Aim 1. By utilizing a biotinylated antibody specific for PD-L1 along with 
fluorescently conjugated streptavidin, we were able to detect PD-L1-positive cells and 
allow for amplification of positive fluorescence. We also performed multiple evaluations 
of monoclonal antibodies specific to either LAG-3 or TIM-3 and determined the 
concentrations at which detection was best for LAG-3+ and TIM-3+ cells.  
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INTRODUCTION 
HIV Etiology and Natural History- 
At present, greater than 35 million people are infected globally with human 
immunodeficiency virus type-1 (HIV-1), and approximately 2 million people were newly 
infected in 20131. The vast proportion of this enormous disease burden is localized in 
underdeveloped regions, particularly Sub-Saharan Africa.  
HIV-1 infection, left untreated, eventually leads to acquired immunodeficiency 
syndrome (AIDS). This disease state is characterized by a wide array of symptoms 
caused by immunologic exhaustion, resulting in multiple opportunistic infections that in 
many cases are fatal. The HIV-1 epidemic was first detected in the early 1980s as a result 
of an usually high incidence of Kaposi’s sarcoma cases and pneumocystis pneumonia, 
diseases not normally found in immunocompetent individuals, being reported in 
homosexual men in the United States2. Similarly, in 1982, Gerstoft et al.3 described four 
cases in Copenhagen of homosexual men presenting in the clinic with symptoms of fever, 
severe weight loss, and lymphadenopathy. Each patient also demonstrated severe 
reductions in T helper cell subsets, poor cellular proliferation, decreased activity of 
natural killer (NK) cells, and impaired cytokine responses to normal antigens. At this 
time, the causative agent was unknown. Gerstoft had suggested a potentially infectious 
cause since each of the patients described had prior sexual contact with other homosexual 
men living in the United States where similar cases were becoming prevalent.   
In 1983, Barré-Sinoussi and colleagues4 were able to isolate a virus from a 
homosexual male with a history similar to those patients described by Gerstoft et al3. 
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This virus was similar, yet distinct, to a recently characterized retrovirus, human T-cell 
lymphotropic viruses (HTLV). Viral specific enzyme activity, termed “reverse 
transcriptase activity” was detected after donated T cells from a healthy individual were 
co-cultured with a sample taken from the lymph node of the patient described. A similar 
experiment was done with cell-free supernatants and again virus-specific reverse 
transcriptase activity was detectable. Interestingly, serum from the source patient did not 
react with antibodies specific to antigens from HTLV-1, and it was determined that the 
virus was distinct from known HTLV strains (types I and II). Thus, this new viral agent 
was subsequently named HTLV III and was considered to be the etiologic agent 
associated with the immunodeficiency syndrome.  This nomenclature was later changed, 
and HTLV-III was re-classified to HIV and the disease was renamed AIDS.   
 
HIV Structure and Genome-  
HIV is a positive-sense, enveloped RNA virus containing “15 proteins and an 
RNA”5. The viral genome contains nine genes necessary for proper virion structure, 
replication, and infectivity: gag, pol, env, tat, rev, vpr, vif, nef, and vpu. The gene 
products of gag, pol, and env are important structural proteins and are translated as large 
protein precursors that are activated by cleavage with the viral protease. The major virus 
structural protein, termed the capsid (CA), and the nucleocapsid (NC) house the viral 
RNA genome as well as reverse transcriptase (RT), protease (PR), and integrase (INT). 
All of these components are critical for the early stages of the viral lifecycle following 
entry into the target host cluster of differentiation 4 (CD4)+ T cells.  Many non-structural 
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gene products activate viral gene expression, such as the HIV transactivator of 
transcription (Tat) protein, while others are responsible for infectivity of newly produced 
virions, such as the viral infectivity factor (Vif) protein. Unlike human DNA 
polymerases, the viral reverse transcriptase has low replication fidelity, allowing many 
erroneous mutations to accumulate with each replication cycle. This high mutation rate 
leads to high HIV genetic diversity even within the same individual that is termed a viral 
swarm or quasispecies 6. This mutation rate is a major feature of HIV-1 pathogenesis and 
underlies the ability of HIV to develop resistance to many antiretroviral treatments 
causing difficulty in the development of a prophylactic vaccine.  
The viral envelope glycoprotein, gp120, which is anchored to the viral membrane 
by the gp41 viral protein, binds the CD4 receptor on a variety of host cells including 
CD4+ T cells, macrophages, and dendritic cells (DCs), and facilitates fusion entry into 
these cells7. Binding of gp120 to an additional co-receptor, predominantly either the 
cysteine-cysteine chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 
(CXCR4)8,9, is also required for fusion and entry. The membrane envelope is acquired 
when a newly assembled virus buds from the host.  Once released into the cytoplasm, the 
reverse transcriptase enzyme transcribes viral RNA into DNA. The viral integrase protein 
then facilitates the integration of HIV DNA into the host cell genome, thus establishing 
infection for the lifetime of the cell (and host). In many cells, the viral genome is quickly 
transcribed and translated to generate new progeny viruses. However, in a subset of cells, 
the viral DNA will remain transcriptionally silent, and the cell will become a reservoir for 
latent virus that has potential to be reactivated in the future10.  
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Two major types of HIV exist: HIV-1 and HIV-2. HIV-1 is more infectious and is 
therefore responsible for the majority of HIV infections worldwide11. HIV-1 and HIV-2 
share the same basic genome structure but sequence homology varies. Based on the 
sequences of two structural genes, gag and env, each HIV type is further classified into 
groups. For HIV-1, four major groups exist: M, N, O, and P. Group M (major) is 
responsible for most HIV-1 infections and can be further divided into nine subtypes12. 
HIV-2 is divided into five groups.  
 
HIV-1 Infection- 
A variety of immune cells are susceptible to HIV infection. Macrophages and 
DCs can be infected; however, CD4+ T cells are the predominant targets13 and are rapidly 
infected and depleted during acute HIV-1 infection. After several weeks, CD4+ T cell 
numbers are partially restored, although they exhibit dramatically impaired functionality, 
including decreased proliferation and cytokine production, a condition termed “T cell 
exhaustion”14.  
In HIV-1 infected patients, infectious virus can be isolated from multiple sources, 
including blood, semen, vaginal secretions, and cerebrospinal fluid. Transmission can 
occur through exchange of infected body fluids during sexual intercourse, from use of 
contaminated needles, from mother to child, and from blood transfusions or organ 
transplantation. While sexual intercourse is a significantly lower-risk transmission route 
compared to others, it accounts for the majority of HIV cases worldwide.  HIV-1 
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infection can be increased by additional factors; for example, presentation of a genital 
ulcer disease can enhance transmission rates.  
The World Health Organization (WHO) defines four major stages of HIV-1 
disease. Patients in stage 1 are highly infectious, have relatively normal CD4 T cell 
counts, and have no detectable HIV-specific antibodies. Patients in stage 2 have rapidly 
increasing viral loads with accompanying decreases in CD4 T cell counts, and 
appearance of HIV-specific antibodies. Patients in stage 3 become increasingly 
immunocompromised, have CD4 T cell counts from 200-500 cells per microliter, and 
exhibit symptoms such as chronic diarrhea, severe weight loss, and fever. Patients in 
stage 4 have CD4 T cell counts below 200 cells per microliter, are at high risk for 
opportunistic infections, and are highly infectious. 
Without intervention, CD4+ T cell numbers as well as immune function 
continually decline during the chronic stages of infection, resulting in AIDS within a 
several years of infection. Patients in advanced stages develop “AIDS-defining 
malignancies” which include Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical 
cancer 15. The rate of disease progression varies dramatically within affected individuals. 
HIV-1 infected individuals can remain asymptomatic for many years. During this latent 
period, individuals may present with vague symptoms such as fever or swollen lymph 
nodes that are typically attributed to other non-specific viral infections. Three patterns of 
disease progression exist: typical, rapid, and long-term non-progressors. Typical 
progressors comprise 50%-70% of those affected and disease progresses over 8-10 years. 
Rapid progressors comprise 5%-10% of those affected and disease progresses over 2-3 
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years. Long-term non-progressors (LTNPs) comprise 5% of those affected. They 
maintain normal CD4+ T cell counts, have viral loads below the level of detection of 
standard viral load assays, and are able to live without disease progression for greater 
than 10 years. LTNPs have been extensively investigated in order to understand the 
genetic, environmental, and immune components that contribute to superior viral control 
with the hope of advancing HIV prevention and therapy.  
With the advent of antiretroviral therapy (ART), patients have been able to live 
much longer and with improved quality of life.  However, despite the vast benefits of 
ARV therapy, patients remain at risk for development of end-organ diseases and 
cumulative ART drug toxicity16. In addition, because ART only targets cells with actively 
replicating virus and does not impact latently infected cells, virus cannot be completely 
eradicated from infected individuals. Therefore, alternative therapies to eradicate or 
“cure” patients need to be explored. Some of these therapies aim to target these latently 
infected cells with the goal of complete virus eradication, termed “sterilizing cure”. 
However, at present this goal is unlikely to be clinically achievable. Other therapies may 
be more practical, such as purging latent virus from hiding, boosting the immune system 
so an infected individual can control viral replication in the absence of ART, or a 
combination of both. These types of therapies have been termed “functional cure”.  
 
HIV and the Immune System 
HIV preferentially targets activated CD4+ T cells17. The chromatin in these cells, 
as opposed to resting CD4+ T cells, is in a state that permits viral DNA integration. As a 
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result, these cells can support the entire viral lifecycle. While most infected cells die 
quickly, a small subset reverts to a resting state of either central or transitional memory 18 
to establish the latent reservoir 19. These memory subsets are ideal reservoirs because 
they are long-lived and in a resting state. 
Even in the presence of therapy, HIV causes chronic hyper-immune activation. 
Levels of interleukin-6 (IL-6), a pro-inflammatory cytokine, were 40%-60% higher in 
HIV+ individuals on suppressive drug therapy compared with well-matched healthy 
controls19. Moreover, the gut mucosa is densely populated with susceptible cells 
expressing the CD4 receptor and the CCR5 co-receptor. Infection of this dense cell 
population is thought to be the cause of irreversible damage to the mucosal barrier 
leading to constant antigen exposure and local immune activation16,18,20.  Hyperimmune 
activation is characterized by highly activated monocytes and macrophages but these 
cells exhibit decreased phagocytosis, defective cytokine production and antibody-
dependent cell-mediated cytotoxicity of NK cells, and a dysfunctional phenotype of T 
cells20. Wilson et al.21 examined immune hyper-activation in the context of lymphocytic 
choriomeningitis infection in mice. One strain was capable of rapid clearance, while the 
other strain established a chronic infection. Mice with chronic infection showed sustained 
elevation of type 1 interferon that was correlated with more rapid disease progression. 
Antigen-presenting cells (APCγ) of chronically infected mice also displayed high 
expression of negative immune regulators and antibody blockade of these negative 
regulators led to improved viral control. Despite the advances of long-term suppressive 
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ART, individuals still remain at high risk for development of cardiovascular disease, 
neurodegenerative disease, osteoporosis, liver damage, kidney failure, and cancer 16.  
Extensive research has gone into the immune responses that are most important 
for viral control. Toll-like receptors (TLRs) have been described as the first “immune 
sensors” activated by infection with HIV-122.  TLR7 and TLR8 are able to recognize 
single-stranded RNA. Recognition of single-stranded RNA by TLR7 on DCs has been 
shown to cause increased secretion of interferon-α (IFNα) and tumor necrosis factory α 
(TNFα)23. NK cells are continually surveying the body for foreign invaders and are 
important in the control of virus replication24. In murine cytomegalovirus, NK cells 
expressing a specific activating receptor, Ly49H, were able to detect a viral protein 
product and rapidly expand in response 25. Alter et al.26 also investigated this 
phenomenon in HIV-1 infection in 2009. Though it was known that NK cells expanded 
rapidly during acute HIV-1 infection, it was unknown whether this was non-specific or 
specific to NK cells expressing the human homolog of Ly49H. NK cells expressing this 
human homolog were found to be specifically expanded during acute HIV infection26.  
Because CD4+ T cells are preferential viral targets and essential for many 
important immune functions, CD4+ T cell counts during infection correlate with disease 
progression and modulations in viral load. Clinically, CD4+ T cell counts are also the 
basis for initiation of ART27. CD4+ T cell counts are normal in LTNPs and their 
peripheral blood mononuclear cells (PBMCs) display an antiapoptotic and pro-T cell 
survival expression profile28. LNTPs also exhibited fewer numbers of memory and naïve 
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CD4+ T cells expressing one of the required co-receptors, CCR5, than those with normal 
HIV-disease progression29.  
 
Simian Immunodeficiency Virus and Non-Human Primate Models of HIV  
Natural primate hosts of simian immunodeficiency virus (SIV), such as sooty 
mangabeys and African green monkeys, exhibit chronic infection with high levels of 
viremia but remain asymptomatic. Infection in a non-natural host such as Asian origin 
macaques produces a disease profile similar to HIV-1 infection in humans 30. Comparison 
of disease progression of SIV in natural and non-natural hosts has been useful to studying 
HIV pathogenesis. For example, in nonpathogenic infection of natural SIV hosts, low 
levels of infection were seen in CD4+ central memory T cells, which strongly suggested 
this cell subset as a key factor in the pathogenesis of HIV infection31,32. Use of non-
human primate (NHP) models has also been essential in understanding HIV susceptibility 
and pathogenesis, and in developing prophylactic and therapeutic interventions. The 
model allows for control of multiple parameters that are otherwise impossible to control 
for in humans, such as time of infection, dose, and route of exposure. It also permits 
extensive sampling of cell and tissue samples from noninfected and infected animals. For 
example, it has resulted in the in-depth understanding of the role of CD4+ T cells and the 
destruction of secondary lymphoid tissues such as the gut mucosa33. The rapid depletion 
of CD4+ T cells is associated with enhanced viral replication, infection of a large 
population of macrophages, and faster disease progression34. Destruction of the gut 
mucosa results in the movement of microbial products into systemic circulation,35 and 
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contributes to the chronic inflammatory state already present, and parallels the same 
condition in HIV-infected patients.  
 
HIV Vaccine and Therapeutic Research- 
The rhesus monkey/SIV model also permits testing of experimental interventions. 
Many candidate vaccines against HIV are being developed and evaluated using this 
model system. In addition, vaccine approaches, such as live attenuated vaccines, have 
been explored with this model. For example, rhesus monkeys, after being vaccinated with 
a modified non-pathogenic SIV strain (SIVmac239delta-Nef), and challenged with a 
subsequent pathogenic SIV strain showed unique protective cluster of differentiation 8 
(CD8)+ T cell gene expression profiles. Expression of genes involved in T cell activation, 
differentiation, signaling, and adhesion was enhanced relative to nonvaccinated 
controls36. Two of the six animals inoculated were resistant to infection with the 
pathogenic strain and the remaining four animals showed substantially improved viral 
control compared with nonvaccinated controls. However, long-term follow-up of these 
animals indicated signs of virus mutation back to full pathogenicity--an unexpected 
setback to the field. Nevertheless, the testing of this modality in monkeys revealed a 
future danger that was circumvented had clinical trials in humans been considered. 
Many other candidate vaccines, such as adeno-associated vaccines, T-cell based 
vaccines, and recombinant herpes vaccines, are being investigated but few have been 
evaluated in human clinical trials. With the recent interest in attaining stabilizing and 
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functional cures of HIV-infected individuals, the NHP model continues to be vital to our 
understanding and treatment of HIV infection.  
Immune anergy, exhaustion, and replicative senescence all describe impaired T 
cell effector function, a situation exacerbated in chronic HIV infection.  Constant 
exposure to foreign antigen leads to expansion of effectors with impaired function, 
increased suppressor T cell numbers, and lack of generation of memory cell subsets. 
Impaired T cell function is predominantly attributed to the up-regulation of negative co-
stimulatory molecules including programmed cell death 1 (PD-1) and its ligands, PD-L1 
and PD-L2, lymphocyte activation gene-3 (LAG-3), and T-cell immunoglobulin mucin-3 
(TIM-3). Expression of these molecules varies across immune cell types and is either 
constitutive or inducible after T cell activation. Each has distinct mechanisms of 
inhibition and effects of binding can be synergistic. In healthy individuals, these 
molecules work to prevent tissue damage caused by strong immune responses but in 
chronically ill patients, such as those with HIV, these molecules help to perpetuate 
infection by dampening immune responses. The involvement of these molecules in HIV 
pathogenesis has been extensively investigated and there is substantial interest in 
understanding how modulating their expression or function can reinvigorate immune 
responses. Because there has been success with antibody blockade of these molecules in 
the treatment of hematologic and solid cancers in which a similar hyper-activated 
immune system also exists37, a similar treatment may be efficacious in treating HIV.  
 
 
	  12 
Aims of Present Study 
Aim 1. Isolation of Cells and RNA for Gene Expression Deconvolution 
Essentially all immune cell subsets are modulated during HIV infection. 
Therefore, it is important to understand not only the basic biology of these cells, but also 
how they may be modulated or targeted for HIV prevention or therapy. There are 
numerous immune cell subsets that can be broadly classified into erythrocytes, platelets, 
T cells, B cells, NK cells, dendritic cells, monocytes, macrophages, mast cells, 
neutrophils, eosinophils, and basophils. Each of these cell subsets can be further 
separated into more detailed cell subsets. For example, T cells can be broadly categorized 
as CD4+ T cells or CD8+ T cells, and each of these groups can be further categorized 
based on its differentiation state, which is broadly classified as naïve (has not seen 
antigen), effector, or memory. Each of these differentiated subsets can be further broken 
down based on permutations of many other parameters, such as activation status, 
cytokine production profile, and transcriptional profile. This latter measure is the most 
sensitive characteristic for distinguishing discrete cell subsets38. Usually, each of these 
cell subsets is studied in isolation or with limited simultaneous consideration of other 
subsets. Nevertheless, to fully understand the dynamic interplay of the virus on the 
immune system, more complex approaches are required. 
Development of whole genome expression profiling has substantially expanded 
our ability to perform highly complex analyses. With the right bioinformatics tools, gene 
expression analysis can identify not only expression changes in a cell subset that are 
associated with different conditions, such as healthy versus diseased individuals, but also 
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changes that occur simultaneously in multiple cell subsets within an individual. 
Historically, in order to perform analyses at the cell subset level, individual cell subsets 
had to be isolated, and the gene expression profile had to be measured for each subset. 
These procedures are technically challenging, time consuming, and also very expensive.  
Recently, a bioinformatics method termed “expression deconvolution” has been 
developed, which allows for the teasing apart of gene expression contributions from 
discrete cell subsets within datasets generated from heterogeneous samples such as whole 
blood. This method is based on the ability to estimate the proportion of the sample to 
which each cell subset contributes. From this information, one can then attribute the 
changes in gene expression in the sample to a specific cell subset. The validity and utility 
of this analysis has been applied to multiple settings. For example, this technique was 
used with known microarray data and a basis matrix in order to elucidate the different 
cell types in blood samples taken from a clinical study. The investigators were able to 
accurately predict the mixing proportions of cell types in the samples, which allowed for 
more accurate analysis of the expression data39.  
In Aim 1 of our research, we are interested in applying expression deconvolution 
analysis in order to enhance gene expression analyses of whole blood samples from SIV-
infected rhesus monkeys involved in experimental SIV therapies. However, 
deconvolution analysis requires an algorithm based on the known expression profiles of 
the individual cell subsets that comprise the sample of interest. This requires isolation and 
gene expression profiling of each individual subset. While such an algorithm has been 
developed for multiple types of human samples, one does not currently exist for rhesus 
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monkeys. We will contribute to establishing this algorithm for rhesus monkeys by 
developing methods to target immune cell subsets from peripheral blood for 
identification and cells sorting for the isolation of associated RNA.  
 
Aim 2. Evaluation of Immune Checkpoint Antibody Panels 
HIV causes not only rapid depletion of immune cells but also impaired 
functionality of remaining cells. Virus-specific T cells exhibit functional senescence and 
have impaired cytokine production14. T cell responses require two signals: (1) stimulation 
by antigen bound to the major histocompatibility complex (MHC) of APCγs at the T cell 
receptor (TCR) and (2) co-stimulation by either positive or negative regulatory 
molecules. Infection leads to sustained elevation of pro-inflammatory cytokines 21 that 
contribute to a state of immune hyperactivation despite control of viremia.  
Immune hyperactivation leads to increased expression of inhibitory molecules on 
immune cells in an attempt to limit immune-mediated tissue damage. Binding of these 
inhibitory molecules, also called immune checkpoint molecules, promotes the 
downregulation of T cells by means of distinct mechanisms. For example, PD-1 binding 
to its cognate ligands, PD-L1 or PD-L2, directly antagonizes TCR and CD28 activation 
of phosphoinositide-3 kinase (PI3K), which results in reduced T cell glucose 
metabolism14. Considerable research has gone into developing treatments that will 
eradicate virus from the body by targeting these checkpoint molecules. Inhibitory 
molecules such as LAG-3, TIM-3, and PD-1, as well as its ligands, PD-L1 and PD-L2, 
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are being investigated to more clearly identify their roles in T cell dysfunction and T cell 
exhaustion. 
In Aim 2 of our research, we will explore the expression of selected immune 
inhibitory proteins in both SIV-infected and noninfected animals. In particular, because 
of their central role in defective immune responses, we will examine three molecules, 
PD-L1, LAG-3, and TIM-3. Using whole blood of SIV-infected and noninfected rhesus 
monkeys, we will develop a strategy utilizing antibody staining and flow cytometry to 
quantify expression of these checkpoint molecules.  
	  16 
MATERIALS AND METHODS 
Deconvolution 
Animals 
Indian-origin rhesus monkeys (Macaca mulatta) were monkeys were housed at 
Bioqual Inc. (Rockville, MD) in accordance with the guidelines outlined in the National 
Institues of Health Guide for the Care and Use of Laboratory Animals and with the 
approval of the Institutional Animal Care and Use Committee of Harvard Medical School 
and the National Institutes of Health.  
 
Sample Processing for Peripheral Blood Mononuclear Cells (PBMCs) 
Ethylenediaminetetraacetic acid (EDTA)-preserved blood whole blood was 
typically first centrifuged at 2500rpm for 15min at room temperature (RT) and the buffy 
coat layer of leukocytes was collected. These cells (or whole blood directly, if no buffy 
coat was isolated first) were layered onto Ficoll (1.077 g/mL) (GE Healthcare, Pittsburgh, 
PA) to isolate PBMC by density gradient centrifugation. PBMCs were collected and 
rinsed with a wash buffer of 1X phosphate-buffered saline (PBS) (Gibco; Life 
Technologies, Carlsbad, CA) supplemented with 2% heat-inactivated fetal bovine serum 
(FBS) (HyClone, GE Healthcare, Pittburgh, PA). When necessary, red blood cells were 
removed by lysis with ammonium-chloride potassium (ACK) buffer (150mM ammonium 
chloride, 10mM potassium bicarbonate, and 30mM EDTA in water) for 3-5 minutes, 
followed by rinsing with wash buffer. PBMCs either were used immediately or 
cryopreserved in 10% dimethylsulfoxide (DMSO) in FBS and thawed upon use. 
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Cryopreserved PBMC were thawed for 1min in 37°C water bath and washed with pre-
warmed RPMI 1640 medium (Cellgro, Corning, NY) with 10% FBS. 
 
Antibody Staining for Flow Cytometry 
If PBMC were cryopreserved, PBMCs were re-suspended in 1XPBS and stained 
with Amine Live/Dead viability dye (Invitrogen, Cambridge, MA) for 20min at RT in the 
dark and then washed with 1XPBS. Fresh or cryopreserved PBMCs were then re-
suspended in wash buffer and stained with antibody cocktails in the dark at RT for 
15min. Cells were washed once, re-suspended in a solution of 2% paraformaldehyde 
(Polysciences, Inc., Warrington, PA) in 1XPBS (fix buffer), and analyzed by flow 
cytometry using a BD LSRII Analyzer (BD Biosciences, San Jose, CA). Data were 
analyzed on FlowJo software (FlowJo, LLC, Ashland, OR). 
 
Flow Cytometric Cell Sorting 
Antibody-stained cells were re-suspended in 1XPBS and maintained on ice. Cells 
were sorted using a BD FACS Aria cell sorter (BD Biosciences, San Jose, CA). Sorted 
cells were either collected either into RNA Protect (QIAGEN, Valencia, CA) at RT or 
into TRIzol LS (Life Technologies, Carlsbad, CA) at RT. Cells sorted into RNA protect 
were centrifuged at 1,000 x g for 10min, supernatant aspirated, and then resuspended in 
standard TRIzol (Life Technologies, Carlsbad, CA) and stored at -80°C. Cells sorted into 
TRIzol LS were directly stored at -80°C. 
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Neutrophil Isolation 
Stock Percoll (1.13 g/mL) (GE Healthcare, Pittsburgh, PA) was made isotonic by 
combining 9 parts stock Percoll with 1 part 10X PBS. The density of the isotonic Percoll, 
as well as the calculations for volumes needed to make less dense Percoll solution from 
the isotonic Percoll, were determined using the following equation: 
Vx = V0 
(!"!  !!)(!!!!!) 
 
V0 is the volume of starting Percoll. ρ0 is the density of starting Percoll. ρi is the density 
of solution that the Percoll will be diluted in. ρm is the target density of the diluted 
Percoll solution. Vx is the volume of diluting solution required to reach the target density 
given the volume of starting Percoll  (V0). The densities of diluting medias (either 
1XPBS or RPMI1640) were assumed to be the same, at 1.006 g/ml) 
Heavy Percoll was layered beneath 1.077 g/mL Percoll. Buffy coat sample was 
layered on top of 1.077 g/mL Percoll. The sample was centrifuged at 3000rpm for 20-
30min at RT. Cells at the interface between the light and heavy Percoll’s, as well as cells 
above the 1.077 g/mL layer and cells within both Percoll layers, were collected and 
washed with wash buffer. Cells were either directly resuspended in fix buffer or first 
stained with indicated antibodies, washed, and then resuspended in fix buffer. 
 
RNA Isolation and Quantification 
The cells in frozen in TRIzol were thawed and spun down at 12,000 x g for 15min 
at 4°C. The aqueous top layer was removed and an equal volume of 100% ethanol was 
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added. The sample was then transferred to an RNeasy mini spin column (QIAGEN, 
Valencia, CA). The sample was centrifuged for 15 s at 8000 x g and the supernatant was 
discarded. The sample was then processed according to the manufacturer’s instructions 
(Qiagen RNAeasy Kit, Valencia, CA). Isolated RNA was analyzed on an Agilent 2100 
bio-analyzer using either a Pico or Nanochip (Agilent Technologies, Santa Clara, CA). 
 
Flow Cytometry “Exhaustion Panel” Optimization 
Antibody staining for flow cytometry 
If PBMC were cryopreserved, PBMCs were resuspended in 1XPBS and stained 
with Amine Live/Dead viability dye for 20min at RT in the dark and then washed with 
1XPBS. Fresh or cryopreserved PBMCs were then resuspended in ice-cold wash buffer. 
For staining with biotinylated antibodies, cells were incubated on ice with the antibody 
for 1hr. Cells were then wash twice with ice-cold wash buffer. Cells were resuspended in 
ice-cold wash buffer. Fluorescently labeled antibodies were then added. If already stained 
with biotinulated antibody, cells were also simultaneously stained with fluorescently 
labeled streptavidin (SA). Cells were incubated on ice for 30min in the dark. Cells were 
then washed twice in wash buffer, resuspended in fix buffer, and collected on the BD 
LSRII Analyzer. Data were analyzed on FlowJo software (Tree star). 
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RESULTS 
Aim 1. Isolation of Cells and RNA for Gene Expression Deconvolution 
Flow Cytometric Antibody Panel Development 
Major immune cell subsets in the peripheral blood were selected to be sorted for 
RNA expression analysis: neutrophils, plasmacytoid dendritic cells (pDCs), myeloid 
dendritic cells (mDCs), monocytes, B cells, CD4+ T cells, CD8+ T cells, and NK cells. 
Cell surface protein expression patterns were used to define each of these target subsets. 
B cells, CD4+ T cells, CD8+ T cells, and NK cells were separated further into resting and 
activated subsets (Table 1).  
Panel Name Antigens Detected Target Cell 
Populations 
Cell Population 
Definition 
 
 
 
T Cells 
 
 
CD3, CD4,  
CD8, CD38, 
HLA-DR 
CD4+ Resting CD3+ CD4+ CD8- 
CD38- HLA-DR- 
CD4+ Activated CD3+ CD4+ CD8- 
CD38+ HLA-DR+ 
CD8+ Resting CD3+ CD4- CD8+ 
CD38- HLA-DR+ 
CD8+Activated  CD3+ CD4- CD8+ 
CD38+ HLA-DR+ 
 
 
 
NK/B Cells 
 
 
CD3, CD8,  
CD14, CD20,  
CD69, NKG2A 
B cell Resting CD3- CD14- CD20+ 
CD69- NKG2A- 
B Cell Activated CD3- CD14- CD20+ 
CD69+ NKG2A- 
NK Resting CD3- CD8+ CD14- 
CD20- CD69- NKG2A+ 
NK Activated  CD3- CD8+ CD14- 
CD20- CD69+ NKG2A+ 
 
 
 
DC/Monocytes 
 
 
NKG2A, CD3, CD20, 
CD14, HLA-DR, 
CD123, CD11c 
Monocytes  NKG2A- CD3- CD20-
CD14+  
DC-plasmacytoid NKG2A- CD3- CD20-
CD14- HLA-DR+ 
CD123+ CD11c - 
DC-myeloid NKG2A- CD3- CD20-
CD14- HLA-DR+ 
CD123- CD11c + 
Table 1 Antibody Panels for Immune Cell Subset Sorting  
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Activated T cells were defined initially by co-expression of HLA-DR and CD3840,41 
while activated B cells and NK cells were defined by expression of CD69. Based on our 
definition of each cell subset, three panels of fluorochrome-labeled antibodies were 
selected to identify and sort each subset by flow cytometry (Table 1). Neutrophils were 
to be identified by light scattering properties alone.  Each of the three antibody panels 
were evaluated for the presence of unfavorable interactions between fluorochromes and 
the ability to clearly identify the cell subsets of interest.  
PBMCs were isolated from whole blood samples from SIV-naïve rhesus monkeys 
using Ficoll density gradient centrifugation and cell samples were stained with each of 
the test panels. Representative staining and gating for each panel is shown in Figure 1. 
For each panel, cell doublets were excluded and live cells were selected from within the 
single cell population. Among the live cells, a large gate was created that included both 
lymphocytes and monocytes (Figure 1A). From within this gate, either T cells, B cells 
and NK cells, or monocytes and DCs were analyzed, depending on the panel. For the T 
cell panel, expression of CD3 was used to identify T cells, which were subsequently 
separated into CD4+ and CD8+ T cells (Figure 1B). For the B cell and NK cell panel, 
CD14+ monocytes were first excluded. B cells were identified by expression of CD20 and 
lack of expression of NKG2A. NK cells were identified by lack of expression of CD20 
and co-expression of CD8 and NKG2A (Figure 1C). In the monocyte and DC panel, T 
cells, B cells, and NK cells were excluded by selecting CD3-CD20-NKG2A- cells. 
Monocytes were identified based on expression of CD14. DCs were identified based on 
the lack of expression of CD14 and the expression of HLA-DR. The pDCs and mDCs 
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were further identified based on expression of CD123 and CD11c respectively (Figure 
1D).  
 
 
Figure 1 Identification of immune cell subsets by flow cytometry 
Flow plots show representative staining and identification of immune cell subsets from rhesus 
PBMC samples. (A) Initial gating strategy used for all antibody panels to exclude cell doublets 
and dead cells, and select lymphocytes and monocytes for further analysis. (B) T cell panel (C) 
NK/B cell panel (D) DC/monocyte panel. Black arrows indicate the selection of a cell subset used 
in subsequent gating. Green arrows indicate the final subset selected.   
 
 
This analysis indicated that there were not any unfavorable interactions between 
fluorochromes. In addition, all target populations could be clearly identified. However, 
the frequency of CD38+HLA-DR+ T cells was extremely low and would be insufficient 
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for sorting (Figure 2A). To address the low frequency of these CD38+HLA-DR+ T cells, 
the combination of HLA-DR and CD38 as the definition of an activated T cell was 
replaced with CD69 as an activation marker 42. To confirm that this revised panel was 
appropriate, cryopreserved PBMC from two monkeys were stained with the updated T 
cell antibody panel and analyzed by flow cytometry.  
 
 
Figure 2 Cytometric identification of activated T cell subsets  
Flow plots show rhesus PBMCs that were stained with antibody panels containing either HLA-
DR and CD38 or CD69 to identify activated T cells. (A) T cell panel containing HLA-DR and 
CD38. (B) T cell panel containing CD69. Right: CD4+ T cells. Left: CD8+ T cells.  
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The frequency of CD69+ T cells was substantially higher than CD38+HLA-DR+ T cells in 
the previous samples (Figure 2B) and was considered appropriate for sorting. Moreover, 
there were no apparent adverse interactions between fluorochromes in this revised panel.   
From our antibody panel evaluations, we determined that neutrophils could not 
reliably be reliably identified by light scattering properties alone (data not shown). To 
address this issue, we developed a separate neutrophil isolation procedure. Also, because 
red blood cell (RBC) contamination in our first panel evaluation exacerbated the 
difficulty in neutrophil identification, we added a density centrifugation step prior to all 
cell isolation protocols that allowed for separation of RBCs from total white blood cells 
(buffy coat).  
To isolate neutrophils, we first evaluated a commercially available separation solution 
comprised of diatrizoate and Dextran 500 (Cedarlane Laboratories, Burlington, Ontario, 
Canada), which had been previously used to isolate neutrophils from human blood 
samples 43. Because this solution was too dense, no cells from rhesus peripheral blood 
passed through the solution after centrifugation (data not shown). We subsequently 
evaluated a commercially available Ficoll solution with density of 1.084 g/mL. We 
layered this heavier Ficoll beneath the standard Ficoll solution with density of 
1.077g/mL. As expected, six layers were visible after centrifgugation for 20 minutes. The 
PBMC layer, 1.077 g/mL Ficoll layer, presumed neutrophil layer, and 1.084 g/mL Ficoll 
layer were each harvested and analyzed by flow cytometry. The top layer of media and 
the RBC pellet were discarded. Samples were evaluated for percent neutrophil 
enrichment by determining percentage of neutrophils. Representative data for this 
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analysis are shown in Figure 3A. The presumed neutrophil layer was enriched in 
neutrophils, as determined by their forward-scattered (FSC) light and side-scattered 
(SSC) light properties. However, there was also a substantial amount of neutrophils that 
had passed into the 1.084 g/mL Ficoll layer.  
We next evaluated two densities of Percoll, 1.0875 g/mL and 1.09 g/mL, layered 
under Percoll of density 1.077 g/mL. As expected, these samples also formed six distinct 
layers after a 20-minute centrifugation. Again, the PBMC layer, 1.077 g/mL Percoll 
layer, presumed neutrophil layer, and each of the heavier Percoll layers were each 
harvested. For enhanced identification of neutrophils, samples were stained with 
fluorochrome-labeled antibodies specific to CD14 and CD11b and analyzed by flow 
cytometry. Neutrophils are CD11b+ and CD14dim. Representative data for this analysis 
are shown in Figure 3B,C.  
In our first round of isolation using Percoll, we obtained greater than 95% 
neutrophils in the neutrophil layer. However, there were a substantial number of 
neutrophils that remained in the 1.077 g/mL Percoll layer. A considerable number of 
neutrophils were also found in the heavier Percoll layers, although there were relatively 
fewer neutrophils in the 1.09 g/mL layer than in the 1.0875 g/mL layer. We repeated 
these isolation procedures and increased our centrifugation time to 30 minutes. By doing 
this, we were able to pull down the neutrophils from the 1.077 g/mL Percoll layer into the 
neutrophil layer and at the same time retain substantial enrichment of neutrophils in the 
presumed neutrophil layer. Greater numbers of neutrophils passed into the 1.0875 g/mL 
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Percoll layer compared with the 1.09 g/mL. Based on these results, we chose the 1.09 
g/mL Percoll for future neutrophil isolations.  
 
Figure 3 Development of neutrophil isolation procedure 
(A) Neutrophil isolation using 1.084 g/mL Ficolll. 2,000 cells are displayed in each plot. 
Neutrophils were gated based on light scattering properties. (B) Neutrophil isolation using 1.0875 
g/mL Percol. Top row: CD11b+CD14dim cells were selected. 3,000 events are displayed in each 
plot. Bottom Row: Neutrophils identified by FSC and SSC. 2,000 events are displayed in each 
plot. (C) Neutrophil isolation using 1.09 g/mL Percoll. Top row: CD11b+CD14dim were selected. 
3,000 events are displayed in each plot. Bottom Row: Neutrophils identified by FSC and SSC. 
2,000 events are displayed in each plot.  
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Optimization of Cell Sorting Procedure for Downstream RNA Isolation and Whole 
Genome Expression  
In order to determine the minimum number of cells that yields sufficient amounts 
of RNA for gene expression analysis, different quantities of total CD4+ T cells and CD8+ 
T cells were sorted by flow cytometry. Samples were prepared, with numbers ranging 
from 5x103 to 1x106. In initial samples, unsorted cell samples were maintained on ice 
until sorted. Sorted cells were collected into RNAprotect and maintained at room 
temperature. RNA was extracted from each sorted sample and the quantity and quality of 
extracted RNA was determined. The quality of RNA (intact or degraded) was measured 
by the RNA integrity number (RIN). RIN values range from 0 to 10, with 10 indicating 
the highest level of RNA quality44. The RINs from all samples were high, ranging from 
7.9 to 10 for CD4+ T cells and 7.4 to 10 for CD8+ T cells. These RIN values indicate 
highly intact and good quality RNA from our sorted populations. Surprisingly, there was 
no correlation between cell number and RNA quantity (Table 2).  
T Cell Type Cell Number Total RNA Yield (ng) 
CD4 5,000 300.96 
CD4 10,000 491.64 
CD4 25,000 297.12 
CD4 50,000 583.08 
CD4 100,000 421.76 
CD4 250,000 424.00 
CD4 500,000 584.48 
CD4 942,500 436.32 
CD8 5,000 259.20 
CD8 10,000 379.80 
CD8 25,000 195.60 
CD8 50,000 283.80 
CD8 100,000 272.16 
CD8 250,000 211.52 
CD8 500,000 398.56 
CD8 675,500 272.16 
Table 2 RNA Yields from Cell Sorting 
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We repeated the cell sorting and RNA extraction with modifications to the sorting 
protocol. In the first sort, we had sorted cells into RNAprotect, pelleted the cells by 
centrifugation, removed supernatant by vacuum aspiration, and resuspended the cells in 
TRIzol for storage and extraction. We hypothesized that cells were lost during the 
aspiration step. Therefore in our next sort, we sorted directly into a concentrated form of 
TRIzol, TRIzol LS, to avoid the pelleting and aspiration steps. This also allowed 
extraction directly from our sorted cell suspensions. The RNA yields from the cells sorted 
with this modified procedure showed improved correlation with cell number for samples 
with at least 2.5x105 cells. Likewise, RNA quality was acceptable only in samples with at 
least 2.5x105 cells. 
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Aim 2. Evaluation of Immune Checkpoint Antibody Panels 
PD-L1 
Using freshly isolated PBMCs from SIV-naïve monkeys, we performed titrations 
using a commercially available monoclonal antibody specific for the checkpoint 
molecule, PD-L1. The molecule was directly conjugated to the fluorochrome 
phycoerythrin-cyanine 7 (PE-Cy7). Upon analysis, we found substantial non-specific 
staining of multiple immune cell subsets and determined that this antibody was not 
appropriate for use in subsequent experiments (data not shown).  
Next, we performed multiple titrations to evaluate a different antibody clone 
specific for PD-L1. This antibody was conjugated to biotin and streptavidin (SA) 
conjugated to two different fluorochromes were used for detection. Our initial testing was 
done with SA conjugated to allophycocyanin (APC) but subsequent evaluations were 
done with SA conjugated to brilliant violet 421 (BV421). We chose to use a biotin-SA 
staining method because PD-L1 is expressed at extremely low levels on T cells. The 
biotin-SA method amplifies fluorescent signals compared with a directly conjugated 
antibody, thus increasing our ability to detect a positive signal. In addition, SA has high 
affinity and specificity for biotin and therefore should not contribute to background 
fluorescence45.  
Using cryopreserved PBMCs from two SIV-naïve monkeys, we tested the PD-L1-
biotin antibody. One-half of the cells were stimulated overnight with phorbol 12-
myristate 13-acetate (PMA) and ionomycin and the other half were left unstimulated. 
Five concentrations of PD-L1-biotin were evaluated: 1.25, 2.5, 5, 10, and 20 µg/mL. The 
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concentration of SA- APC was kept constant at 1 µg/mL. We analyzed B cells, NK cells, 
T cells, and monocytes. All concentrations that were tested showed similar staining. A 
representative plot is given in Figure 4.   
 
Figure 4 PD-L1 staining of T cells stimulated with PMA/Ionomycin  
Representative flow plot shows PD-L1 staining on stimulated T cell. The biotin-labeled anti-PD-
L1 antibody was titrated between 1.25 and 20 µg/mL. All concentrations showed similar staining 
to that of the lowest concentration (1.25 µg/mL). 
 
Because there was similar staining at all concentrations of the PD-L1 antibody, 
we retitrated it at lower concentrations. We chose to test concentrations of 0.75, 1.5, and 
2.5 µg/mL. The concentration of SA-BV421 was kept constant at 1 µg/mL. Cells from 
two SIV-naïve monkeys were split, with one-half being stimulated with PMA and 
ionomycin overnight and the other half being left unstimulated. Upon analysis, we noted 
substantial background staining for B cells as well as T cells, even at the lowest 
concentration for both stimulated and unstimulated cells. Representative flow plots for 
both B and T cells are shown in Figure 5A.  
The persistence of high background staining led us to test one additional set of 
PD-L1 antibody concentrations: 0.1, 0.25, 0.75, and 1.5 µg/mL. The concentration of SA- 
CD8 
PD-­‐L1 
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BV421 was kept constant at a lower value of 0.25 µg/mL. Staining was performed with 
cryopreserved PBMCs from one chronically infected monkey and one naïve monkey.  
 
Figure 5 PD-L1 Titrations (A) Representative flow plots for staining of B (left) and T  (right) 
cells with PD-L1-biotin-SA-BV421. Shaded gray histograms represent background fluorescence 
in the absence of antibody. Green: 0.75 µg/mL, blue: 1.5 µg/mL, red: 2.5 µg/mL. (B) Ex vivo PD-
L1 staining at 0, 0.1, 0.25, 0.75, and 1.5 µg/mL. Top row: B cells. Bottom row: T cells.  
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There was no positive staining using 0.1 µg/mL of antibody. Modest background staining 
was observed using 0.25 µg/mL. While the level of background staining was higher, 
particularly on T cells using 0.75 µg/mL, this higher concentration appeared necessary to 
detect PD-L1+ B cells (Figure 5B). Therefore, the final antibody concentration chosen 
for PD-L1 was 0.75 µg/mL. 
Finally, we performed titrations of SA-BV421. We tested SA-BV421 at 
concentrations of 0.5, 1, and 2 µg/mL. The antibody against PD-L1 was kept constant at 
2.5 µg/mL. Cells were stimulated with PMA and ionomycin overnight. Staining of was 
similarly strong among all concentrations (data not shown). We then tested SA-BV421 at 
concentrations of 0.25, 0.5, and 1 µg/mL while the concentration of the anti-PD-L1 was 
kept constant at 2.5 µg/mL. Staining was similarly strong among all concentrations tested 
(data not shown). Therefore, the final antibody concentration for SA-BV421 chosen was 
0.25 µg/mL.  
 
LAG-3 
We performed multiple titrations of a monoclonal antibody specific for another 
checkpoint molecule of interest, LAG-3, conjugated to the fluorochrome phycoerythrin 
(PE). Cryopreserved PBMCs from two SIV-naïve monkeys were thawed and split, with 
one half being stimulated with concanavalin (ConA) or left unstimulated. We evaluated 
the anti-LAG-3 antibody at concentrations of 2.5, 5, 10, 20, 40, and 100 µg/mL. T cells 
were analyzed and positive populations were detected even at the lowest concentration 
(2.5 µg/mL) for both stimulated and unstimulated cells (Figure 6A). At higher 
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concentrations, the amount of background staining increased substantially (data not 
shown).  
 
Figure 6 LAG-3 titration  
(A) Flow plots show staining of T cells with anti-LAG-3 in both unstimulated and stimulated 
samples at 2.5  and 5 µg/mL. (B) Flow plots show staining of T cells with anti-LAG-3 antibody in 
unstimulated samples and 1.25 and 2.5 µg/mL.  
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Because positive staining was observed at the lowest concentration tested (2.5 
µg/mL), the anti-LAG-3 antibody was titrated at lower concentrations (0.3, 0.6, 1.25, and 
2.5 µg/mL) on unstimulated cells from two additional monkeys. Separation of LAG-3+ 
cells was best seen at 2.5 µg/mL (Figure 6B) and we chose this value as our final 
antibody concentration.  
 
TIM-3 
We performed multiple titrations of a monoclonal antibody specific for another 
checkpoint molecule of interest, TIM-3. Ex vivo staining was performed on PBMCs from 
two chronically SIV infected monkeys. The TIM-3 antibody conjugated to the 
fluorochrome AlexaFluor488 (A488) was tested at concentrations of 2.5, 5, 10, and 20 
µg/mL. We were most interested in expression of TIM-3 in T cells. Upon analysis, there 
was increased background staining of T cells at and above 10 µg/mL (Figure 7A). 
Background staining of T cells at 2.5 µg/mL and 5 µg/mL was similar to that 
without antibody, while higher concentrations of 10 µg/mL and 20 µg/mL gave 
significantly increased background staining. Unexpectedly, we also observed positive 
staining of a subset of B cells (Figure 7B). These concentrations were again tested but on 
PBMCs after stimulation with ConA for 3 days.  
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Figure 7 TIM-3-A488 staining 
(A) Flow plots show TIM-3 staining on T cells at 10 µg/mL. Staining at concentrations greater 
than 10 µg/mL was similar. Histograms show staining of all concentrations evaluated. The shaded 
area represents background fluorescence in the absence of antibody. Blue: 2.5 µg/mL, green: 5 
µg/mL, orange: 10 µg/mL, red: 20 µg/mL. (B) Flow plot shows TIM-3 staining on B cells.  
 
 
Staining was compared with the same antibody conjugated to the fluorochrome APC, 
which had been titrated previously. T cells were analyzed for TIM-3 expression. Both 2.5 
and 5 µg/mL of the A488 conjugate showed similar staining to the APC conjugate at 10 
µg/mL (Figure 8)	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Figure 8  Detection of TIM-3+ T cells with A488 and APC conjugates  
Staining of T cells by the anti-TIM-3 antibody. T cells were stained with the A488 conjugate are 
compared to those stained with the APC conjugate.  
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DISCUSSION 
Aim 1. Isolation of Cells and RNA for Gene Expression Deconvolution 
A majority of immune cell subsets are modified during HIV infection. There is 
considerable interest in understanding the nature of these changes to help facilitate the 
development of HIV immunotherapies. Whole genome expression analysis facilitates a 
detailed understanding of biological perturbations on a cellular level. A recent 
bioinformatics method, expression deconvolution, utilizes existing gene expression data 
to measure changes of discrete cell subpopulations within a heterogeneous cell sample. 
While the tools for this method have been developed for human samples, they do not 
exist for rhesus monkey samples. Therefore, we took the first steps in the process of 
developing these bio-informatic tools for rhesus monkeys. This process required 
developing methods to detect rhesus immune cell subsets from peripheral blood and 
isolate their RNA. Major peripheral blood immune cell subsets were chosen to target for 
identification and cell sorting. Definitions of target subsets were based on expression of 
particular cell surface proteins and were further divided based on activation status. Our 
technical assessment of the antibody panels demonstrated that there were no adverse 
interactions between fluorochromes in any of the antibody panels.  
Initially, activated T cells were defined based on positive expression of two 
proteins, HLA-DR and CD38. However, our initial assessment of these proteins as 
markers to identify activated cells found that the frequency of the activated cells was 
remarkably low. This was not the case with our other target cell subsets, which were 
readily identified. To address this issue, we chose to use the expression of the cell surface 
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protein, CD69, as the definition of activated T cells. A revised panel using CD69 as an 
activation marker for T cells was tested and analyzed. The frequency of CD69+ T cells 
was substantially higher than CD38-positive, HLA-DR-positive T cells as defined in the 
original staining panel. Again, no adverse interactions were noted between fluorochromes 
in this revised panel.  
While neutrophils have not been a cell subset of primary focus in HIV research, 
they account for up to 60% of all nucleated cells in the peripheral blood46. Therefore, in 
developing a method for parsing of gene expression signals that belong to different cell 
subsets, it is crucial to identify of and adjust the signal from neutrophils is crucial. We 
initially attempted to sort neutrophils based on their light scattering properties; however, 
this could not be accomplished reliably. As a result, we chose to develop a separate 
neutrophil isolation procedure. Our evaluation of multiple commercially available 
products designed for human blood was unsuccessful. Although, the cellular composition 
and density of cells are similar between humans and rhesus monkeys, there are 
differences that have been previously identified that are substantial enough such that 
products designed for human samples are not compatible with rhesus monkey samples. In 
using density gradient centrifugation for cell subset isolation, the specific cell density 
determines the layer into which the cell populations will segregate. Differences in 
neutrophil density between humans and rhesus monkeys may explain the inability to 
isolate rhesus neutrophils using products designed for human blood.  
This issue led us to assess Percoll concentrations that were slightly less dense than 
the products used for human samples. In doing so, we found that Percoll of density 1.09 
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g/mL was optimal for both yield and purity of rhesus neutrophils (with concomitant 
isolation of PBMCs with a Percoll layer of density 1.077 g/mL). This is similar to a 
previous report in 199147 that demonstrated Ficoll of 1.077 g/mL combined with Ficoll of 
1.100 g/mL was optimal for simultaneous isolation of PBMCs and neutrophils, 
respectively, from rhesus peripheral blood.  
Overall, we successfully developed three antibody panels and a separate Percoll-
based method. When combined, these methods allow for detection and sorting of the 
following immune cell subsets, which account for essentially all nucleated cells in whole 
blood of rhesus monkeys. These immune cell subsets are as follows: monocytes, pDCs, 
mDCs, neutrophils, activated and resting CD4+ T cells, activated and resting CD8+ T 
cells, activated and resting B cells, and activated and resting NK cells.  
To determine the minimum number of cells necessary to yield sufficient amounts 
of RNA for gene expression analysis, we sorted different numbers of total CD4+ T cells 
and CD8+ T cells by flow cytometry. RNA obtained from these cells was subsequently 
analyzed for quality using RIN. RIN values range from 0 to 10, with 10 indicating the 
highest quality RNA. While the quality of RNA obtained from these sorts was high, there 
was no correlation between cell number and total RNA yield. This result suggested that 
either the cells or the RNA was being lost during one of the steps in the protocol.   
Consequently, we repeated our cell sorting and RNA extraction but with minor 
modifications to the protocol. Initially, cells were sorted into RNAprotect and pelleted by 
centrifugation, supernatant was aspirated, and the cells were resuspended in TRIzol. Loss 
of cells during the aspiration step appeared to be the cause of the inconsistency between 
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cell number and RNA yield. In the revised protocol, we sorted cells directly into a 
concentrated form of TrRIzol, TRIzol LS, which allowed for direct extraction. The total 
RNA extracted exhibited improved correlation with cell number but only with 
populations with at least 2.5x105 cells. RIN was also only acceptable at these higher 
populations. Therefore, we successfully optimized a procedure to sort and extract RNA of 
a quality and quantity that was sufficient for downstream whole genome expression 
analysis.  
One potential limitation to this approach is that several of the immune cell subsets 
are extremely rare in vivo. For example, pDCs account for only 0.2% of all white blood 
cells in peripheral blood 48,49. Even from large samples of whole blood, we may not 
obtain the number (2x105 cells) that was determined to be the minimum amount for 
reliable RNA isolation. One alternative approach would be to culture and expand cells in 
vitro. Unfortunately, these cultured cells would need to be modified to allow for 
expansion, which would be contradictory to our goal of providing physiological gene 
expression data in a naïve population. Alternatively, methods have recently been 
developed that allow for whole genome sequencing from a small number of cells, down 
to single cells50. This method could be used to generate whole genome expression data 
from those cell subsets for which the cell numbers sorted ex vivo are insufficient for 
standard whole genome expression methods requiring large cell numbers.  
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Aim 2. Evaluation of Immune Checkpoint Antibody Panels  
HIV infection leads to various detrimental effects on immunity. It creates a state 
of sustained immune hyperactivation21,51 that leads to  end organ damage and disease16 
even with control of viremia. Sustained hyperimmune activation also promotes increased 
expression of negative regulatory molecules (checkpoint molecules) such as LAG-3, 
TIM-3, and PD-1 as well as its ligands, PD-L1 and PD-L2. HIV preferentially infects 
CD4+ T cells and induces their rapid decline. While there is a compensatory expansion of 
virus-specific CD8+ T cells, these cells exhibit broad functional defects related to 
survival, proliferation, cytokine production, and cytotoxic ability52. These defects are 
associated with expression of checkpoint molecules. For example, LAG-3 exhibits 
considerable homology to CD4 and binds MHC II on APCγs to limit T cell activation53. 
Expression of PD-1 is also correlated to plasma viremia20. There is also expansion of 
regulatory T cells that express a variety of these checkpoint molecules including TIM-3 
and cytotoxic T-lymphocyte associated protein 4 (CTLA-4)54,55.  
Binding of these checkpoint molecules with their ligands not only dampens 
immune responses, an action which is necessary to limit immune-mediated tissue 
damage, but also perpetuates the negative effects of HIV infection. Many researchers in 
the field are investigating these molecules to better characterize and understand their 
expression on different immune cell types in hope of targeting them for HIV treatment. In 
fact, antibodies directed against these checkpoint molecules have been used in the 
treatment of different cancers. Anti-PD-1 has been applied to in the treatment of 
hematologic cancers with moderate success37 and anti-CTLA-4, when combined with 
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current therapies has resulted in improved responses to treatment in metastatic melanoma 
patients54. The immune defects observed in cancer are similar to those observed in 
chronic HIV infection. To develop tools to study these molecules in SIV-infected rhesus 
monkeys, we set out to optimize the use of antibodies specific to PD-L1, LAG-3, and 
TIM-3 for use in flow cytometric analysis.  
To detect cells expressing PD-L1, we ultimately chose to use a biotinylated anti-
PD-L1 antibody along with a fluorescently conjugated SA for multiple reasons. It is well 
documented that binding and specificity between biotin and SA are very high45. 
Additionally, the biotin-SA antibody method increases the fluorescent signal, facilitating 
more sensitive detection of positive cells. Finally, the directly conjugated PD-L1 that we 
evaluated showed substantial non-specific staining of immune cells and was unsuitable 
for future experiments.   
Initially, we tested PD-L1-biotin on both stimulated and unstimulated PBMCs. 
PD-L1 is expressed on a subset of B cells and monocytes ex vivo without stimulation and 
is substantially upregulated on these cells upon stimulation. PD-L1 is generally not 
expressed on resting T cells; stimulation is required. Therefore, comparison of stimulated 
and un-stimulated samples was used to assess whether the antibody was binding 
specifically to PD-L1. In stimulated samples, we observed that a substantial percentage of 
all immune subsets exhibited positive staining compared to un-stimulated samples. This 
observation suggested that the antibody was binding to the expected target.  
The range of antibody concentrations used in the first two evaluations showed 
substantial fluorescent signal, even with unstimulated T cells, which should be negative. 
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This situation implied that we were using excessive amounts of antibody leading to non-
specific staining. To address this issue, we tested lower concentrations of antibody along 
with a lower concentration of SA-BV421. Staining with 0.25 µg/mL of SA-BV421 
resulted in minimal background staining; however, it prevented detection of all PD-L1-
positive cells. Conversely, staining with 0.75 µg/mL showed modest increases in 
background staining, but allowed for enhanced detection of PD-L1-positive cells. 
Therefore, the 0.75 µg/mL concentration may be used for future experiments, although 
we must be cautious about misinterpreting low levels of background for true PD-L1-
positive cells. Alternatively, we may consider evaluating a different antibody clone.  
For the detection of cells expressing LAG-3, we stained both stimulated and un-
stimulated cryopreserved PBMCs. LAG-3 has been reported to be expressed on B cells, 
and NK cells, and activated T cells 53. We were most interested in the expression of 
LAG-3 on T cells because of its negative regulatory effects on proliferation and 
activation, which are thought to dampen the immune response against HIV56. During our 
first titration, all concentrations (2.5-100 µg/mL) tested exhibited positive staining of T 
cells. There were substantially higher percentages found in the stimulated samples 
compared with the unstimulated samples, demonstrating the specificity of detection. 
However, the background fluorescence was extremely high at 10 µg/mL and it was not 
clear that even the lowest concentration evaluated (2.5 µg/mL) was the optimal 
concentration. As a result, we repeated the experiment but with lower concentrations of 
antibody with ex vivo PBMCs. Although we saw positive staining at both 1.25 µg/mL and 
2.5 µg/mL, the best detection and separation of LAG-3-positive T cells was at 2.5 µg/mL.  
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 Our final evaluation was of an antibody to detect TIM-3. TIM-3 is expressed on T 
cells, DCs, and monocytes53. We were most interested in TIM-3 expression on T cells 
because of its negative proliferative effects and pro-apoptotic effect on T helper (TH) 
cells55. Our first evaluation of the antibody on un-stimulated cells was not informative, 
since very few T cells express TIM-3 without stimulation. Upon staining of stimulated 
cells, we found that the 2.5 µg/mL concentration gave optimal staining and therefore 
could be used for future experiments.  
Expression of TIM-3 has not been reported in B cells. Thus, we were surprised to find 
apparent specific staining of a subpopulation of B cells with this TIM-3 antibody. It is 
possible that this antibody was detecting another protein in addition to its target protein, 
TIM-3. If this is the case, it may be necessary to evaluate an additional TIM-3 antibody 
clone. Otherwise, the expression of TIM-3 on B cells in these rhesus monkey samples 
may be real, revealing a difference in tissue expression between humans and rhesus 
monkeys. While humans and monkeys share substantial physiology and molecular 
biology, there are a number of subtle differences in protein homology and tissue 
expression that have been reported. For examples, NK cells in humans do not express the 
CD8 molecule, whereas NK cells in rhesus monkeys do. Therefore, we may have 
uncovered such a difference in protein expression. This variation should be explored 
further because knowledge these differences can inform the translation of findings 
between rhesus monkeys and humans.  
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Future Directions 
We have optimized the detection of three proteins that play a central role in the 
defective immune responses against HIV and therefore whose understanding of is vital to 
develop immunotherapies. The fluorochromes conjugated to antibodies targeting these 
proteins were carefully selected in order to allow for optimal protein detection while 
minimizing adverse interactions between them. The next step will be to combine these 
antibodies, as well as additional antibodies, into a comprehensive antibody panel. 
Because some of these additional antibodies will be limited in their fluorochrome 
availability, we had to keep this in mind when selecting the fluorochromes that PD-L1, 
LAG-3, and TIM-3 antibodies were conjugated to. This comprehensive antibody panel 
will not only be able to detect these three proteins simultaneously, but will also be able to 
detect multiple other proteins known to be important for assessing T cell phenotype and T 
cell activation. Therefore, this antibody panel will be critical in detecting, quantifying, 
and tracking the expression of these molecules on immune cell subsets in SIV-infected 
rhesus monkeys, and the results will be vital in developing effective immunotherapies 
against HIV.   
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